Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NYSE - Nasdaq Real Time Price USD

Bausch Health Companies Inc. (BHC)

Compare
6.37
-0.10
(-1.55%)
As of 1:41:08 PM EDT. Market Open.
Loading Chart for BHC
  • Previous Close 6.47
  • Open 6.39
  • Bid 6.39 x 1200
  • Ask 6.41 x 1800
  • Day's Range 6.36 - 6.49
  • 52 Week Range 3.96 - 11.46
  • Volume 412,685
  • Avg. Volume 2,627,043
  • Market Cap (intraday) 2.362B
  • Beta (5Y Monthly) 0.60
  • PE Ratio (TTM) --
  • EPS (TTM) -0.13
  • Earnings Date Apr 30, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Nov 10, 2010
  • 1y Target Est 8.67

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

www.bauschhealth.com

20,700

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BHC

View More

Performance Overview: BHC

Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

BHC
17.59%
S&P/TSX Composite index (^GSPTSE)
1.46%

1-Year Return

BHC
38.75%
S&P/TSX Composite index (^GSPTSE)
12.59%

3-Year Return

BHC
72.35%
S&P/TSX Composite index (^GSPTSE)
13.79%

5-Year Return

BHC
53.67%
S&P/TSX Composite index (^GSPTSE)
93.99%

Compare To: BHC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BHC

View More

Valuation Measures

Annual
As of 3/31/2025
  • Market Cap

    2.40B

  • Enterprise Value

    22.83B

  • Trailing P/E

    --

  • Forward P/E

    1.43

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.25

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.37

  • Enterprise Value/EBITDA

    8.09

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.48%

  • Return on Assets (ttm)

    4.33%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    9.62B

  • Net Income Avi to Common (ttm)

    -46M

  • Diluted EPS (ttm)

    -0.13

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.18B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    1.8B

Research Analysis: BHC

View More

Company Insights: BHC

Research Reports: BHC

View More

People Also Watch